ViatrisRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Viatris (VTRS) reported revenue of $3.76B in Q2 2026, with Brands its largest revenue segment at 65%.
ViatrisViatris sells branded and generic medicines, including Lipitor, Norvasc, EpiPen, Lyrica, Viagra, and Creon, across developed markets, Greater China, JANZ, and emerging markets. The company was formed in 2020 from Mylan and Pfizer Upjohn.
Viatris (VTRS) is a Pharmaceuticals company. Viatris sells branded and generic medicines, including Lipitor, Norvasc, EpiPen, Lyrica, Viagra, and Creon, across developed markets, Greater China, JANZ, and emerging markets. The company was formed in 2020 from Mylan and Pfizer Upjohn. It was founded in 2020, is headquartered in Canonsburg, Pennsylvania and employs about 30,000 people.
As of 2026-Q2, Viatris's revenue breaks down across Brands (65%), Generics (35%). See the revenue-by-segment chart for the full mix.
Track Viatris's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 26, 2026.
Sterling groups Viatris in the Healthcare sector, alongside Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ) and Zoetis (ZTS).
If you are researching Viatris, also look at Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ) and Zoetis (ZTS). You can compare all of them side by side or browse the full Healthcare sector on Sterling.
Q3 2016-Q2 2026
Q3 2016-Q2 2026